Edition:
United Kingdom

Galapagos NV (GLPG.OQ)

GLPG.OQ on NASDAQ Stock Exchange Global Select Market

109.75USD
8:59pm GMT
Change (% chg)

$-1.11 (-1.00%)
Prev Close
$110.86
Open
$110.20
Day's High
$110.84
Day's Low
$109.71
Volume
34,285
Avg. Vol
31,668
52-wk High
$113.03
52-wk Low
$63.69

Chart for

About

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-ProQR And Galapagos Announce Research Collaboration

* PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY

08 Jan 2018

BRIEF-Galapagos Reports Preliminary Topline Results In Osteoarthritis Study

* REPORTED ON SUNDAY, POSITIVE PRELIMINARY TOPLINE RESULTS WITH A PHASE 1B STUDY IN OSTEOARTHRITIS (OA) PATIENTS IN THE UNITED STATES

08 Jan 2018

BRIEF-Galapagos Exercises Co-Promotion Option For Filgotinib

* SAID ON THURSDAY IT WILL OPT-IN ON CO-PROMOTION OF FILGOTINIB WITH COLLABORATION PARTNER GILEAD SCIENCES IN EIGHT EUROPEAN COUNTRIES, SHOULD FILGOTINIB BE APPROVED FOR COMMERCIAL SALE

15 Dec 2017

BRIEF-Galapagos To Enter NASDAQ Biotech Index Effective Dec 18‍​

* TO ENTER NASDAQ BIOTECH INDEX EFFECTIVE DEC 18‍​ Source text: http://bit.ly/2jM5AGV Further company coverage: (Gdynia Newsroom)

11 Dec 2017

BRIEF-Galapagos NV ‍announces share capital increase arising from warrant exercises​

* ‍Announces a share capital increase arising from warrant exercises​

23 Nov 2017

BRIEF-Galapagos NV reports Q3 loss of ‍1.75​ euro per share

* Galapagos NV qtrly ‍revenues 106.4 million euro versus 65 million euro​

26 Oct 2017

BRIEF-Galapagos & Morphosys announce Phase 1 results with joint investigational antibody program MOR106

* Co, Morphosys report first promising signs of clinical activity in phase 1 study with IL-17C antibody MOR106 in Atopic Dermatitis patients

27 Sep 2017

BRIEF-Galapagos says GLPG1690 halts disease progression in IPF patients in mid-stage trial

* GLPG1690 halts disease progression in IPF patients in Flora phase 2A trial

09 Aug 2017

BRIEF-Galapagos H1 revenues up at EUR 73.0 mln

* ANNOUNCED ON THURSDAY H1 REVENUES EUR 73.0 MLN VS EUR 48.8 MLN YEAR AGO

28 Jul 2017

BRIEF-Servier announces it has exercised option to develop osteoarthritis molecule from Galapagos

* SERVIER ANNOUNCES IT HAS EXERCISED OPTION TO DEVELOP NOVEL OSTEOARTHRITIS MOLECULE GLPG1972/S201086 FROM GALAPAGOS NV, OBTAINING GLOBAL COMMERCIAL RIGHTS OUTSIDE THE U.S.

27 Jul 2017

Earnings vs. Estimates